With no explanation, chose the best option from "A", "B", "C" or "D". No. 107-204, 116 Stat. 745 (2002). 142 . See 15 U.S.C. § 7241(a)(4). 143 . See Compl. ¶¶ 75-78. 144 . Id. ¶ 78. 145 . See Caiola, 295 F.3d at 331. 146 . Compl. ¶ 78. 147 . Id. 148 . See id. 149 . See id. V 8. 150 . See id. ¶¶ 131-132. 151 . Novak, 216 F.3d at 309 (quotations omitted). 152 . See Compl. ¶¶ 133-137. 153 . See id. ¶¶ 6, 44, 48-49, 54-56, 62, 108. 154 . In re Scottish Re Group, 524 F.Supp.2d at 392 (quotations omitted). 155 . See Tellabs, 127 S.Ct. at 2511. 156 . See Compl. ¶¶ 8, 130. 157 . See Kalnit, 264 F.3d at 139 (“Motives that are generally possessed by most corporate directors and officers do not suffice; instead, plaintiffs must assert a concrete and personal benefit to the individual defendants resulting from the fraud.”). See also Chemical Bank, 726 F.2d at 939 (<HOLDING>). 158 . See Compl ¶¶ 8, 130. 159 . See In re

A: holding that a claim arises from the purchase or sale of a security only if there is an allegation of fraud in the purchase sale or issuance of the  instrument
B: holding that a private plaintiff is not entitled to maintain an aiding and abetting action under  10b or rule 10b  5
C: holding that a pledge is a sale and purchase of a security under  10b
D: holding that section 10b violation occurs on date of alleged misrepresentation not the date of the sale or purchase of securities
C.